 |
|
|
| |
WEEK 124 OF THE RANDOMIZED, OPEN-LABEL,
PHASE 3 FLAIR STUDY EVALUATING LONG-ACTING
CABOTEGRAVIR + RILPIVIRINE FOR TREATMENT IN
ADULTS WITH HIV-1 INFECTION
|
| |
| |
IAS 2021 July 18-22
Chloe Orkin1, Enrique Bernal Morell2, Darrell H. S. Tan3, Harold Katner4, Yashna Singh5,
Hans-Jürgen Stellbrink6, Elena Belonosova7, Rebecca DeMoor8, Sandy Griffith9, Shanker Thiagarajah8,
Rodica Van Solingen-Ristea10, Susan L. Ford11, Herta Crauwels10, Parul Patel9, Amy Cutrell9,
Kimberly Y. Smith9, Kati Vandermeulen10, Marty St. Clair9, William R. Spreen9, Ronald D’Amico9
1Queen Mary University, London, United Kingdom; 2Hospital General Universitario Reina Sofía, Murcia, Spain; 3Division of Infectious Diseases, St. Michael’s Hospital, Toronto, Canada; 4Mercer University Medical School, Macon, GA, United States; 5Desmond Tutu Health Foundation, Cape Town, South Africa; 6ICH Study Center, Hamburg, Germany; 7Orel Regional Center for AIDS, Orel, Russia; 8GlaxoSmithKline, London, United Kingdom; 9ViiV Healthcare, Research Triangle Park, NC, United States; 10Janssen Research & Development, Beerse, Belgium; 11GlaxoSmithKline, Research Triangle Park, NC, United States
|
| |
|
|
|
|
|
